Enveric Biosciences, Inc. (ENVB): Nasdaq/NYSE listing notice — Enveric Biosciences receives Nasdaq deficiency notice for failing minimum equity requirement

Enveric Biosciences, Inc.

Nasdaq notified Enveric on Aug 26, 2025 that stockholders' equity of $2.18M as of June 30, 2025 is below $2.5M minimum.
Company has until Oct 10, 2025 to submit a plan to regain compliance; Nasdaq may grant a 180-day extension if plan is accepted.
If plan is rejected, Company may appeal to a Nasdaq Hearings Panel.
Company intends to submit a compliance plan and consider available options to regain compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Enveric Biosciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

August 26, 2025, Enveric Biosciences, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’Equity Requirement”). The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2025, r

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-026040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.